FGF-2 Modulating Compounds for Stroke Recovery
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for stroke and other brain injuries lack effective methods for enhancing recovery and improving mobility in stroke survivors, with existing growth factors like FGF-2 being challenging to use due to their size and complexity.
Innovation Solution
Development of compounds that modulate FGF activity and enhance the binding between FGF-2 and its receptors, such as FGF-R1, to treat various diseases and injuries including stroke, traumatic brain injury, and other neurological conditions.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If FGF-2 is used as a therapy for stroke, then neuronal survival and recovery are improved, but the treatment complexity and difficulty of administration increase due to the polypeptide's size and structure
Solution Approach 1:
The patent extracts the critical signaling function of FGF-2 by developing small molecule compounds that mimic and enhance FGF-2 receptor binding. Instead of administering the complex 155-amino acid polypeptide, the invention uses simplified molecular structures (such as compounds with specific heterocyclic cores and substituent patterns) that capture the essential therapeutic effect through receptor interaction, eliminating the administrative complexities of polypeptide delivery.
Solution Approach 2:
The patent creates simplified molecular copies or analogs that replicate the key functional properties of FGF-2. These small molecule compounds are designed to bind to FGF receptors and trigger the same downstream signaling pathways (MAPK/ERK, PI3K/Akt) that endogenous FGF-2 activates, providing therapeutic benefit through a structurally simplified surrogate that is easier to administer and stabilize.
2Productivity
If FGF-2 is administered to enhance spontaneous recovery, then neuronal sprouting and synapse formation increase, but the molecular complexity and manufacturing challenges increase
Solution Approach 1:
The patent extracts the essential pharmacophoric elements required for FGF receptor activation from the complete FGF-2 polypeptide structure. By identifying and isolating the critical molecular features needed for receptor binding and signaling activation, the invention develops simplified small molecule compounds that can be manufactured through conventional organic synthesis rather than complex biotechnological processes required for polypeptide production.
Solution Approach 2:
The patent fundamentally changes the molecular parameters from large polypeptide (155 amino acids, ~18 kDa) to small molecule compounds with defined molecular weights, solubility characteristics, and stability profiles. This parameter transformation enables easier manufacturing, storage, and formulation while maintaining the ability to stimulate neuronal sprouting and synapse formation through FGF receptor activation.
Data Source
AI summary
The invention features compounds and a method of treating an injury or a disease e.g., stroke, congenital hypogonadotropic hypogonadism, and viral infection, using the compounds. Also featured is a pharmaceutical composition containing one or more of the compounds, and a method of increasing spermatogenesis using the compounds.